← Back to Search

POSTHOC app for Symptoms (POSTHOC Trial)

Phase 1 & 2

Recruiting

Led By Amber Kleckner, PhD

Research Sponsored by University of Maryland, Baltimore

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 weeks

Awards & highlights

POSTHOC Trial Summary

"This trial is testing a new app called POSTHOC that digitizes Survivorship Care Plans for cancer survivors. The app aims to help patients track their health behaviors and compare them to clinical goals. The

Who is the study for?

This trial is for cancer survivors who've recently finished treatment like chemo, radiotherapy, or surgery. They should be open to following a Survivorship Care Plan and have access to a smartphone with internet. Participants must be adults who can read English and consent to the study.Check my eligibility

What is being tested?

The POSTHOC app is being tested against usual care plans in managing symptoms after cancer treatment. The app digitizes care plans and integrates them with health trackers. Patients will focus on nutrition or exercise goals over 12 weeks.See study design

What are the potential side effects?

Since this trial involves using an app rather than medication, traditional side effects are not expected. However, participants may experience stress or frustration if they encounter technical issues or find it challenging to follow the digital plan.

POSTHOC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cumulative number of times participants log/view data in the app

Likely to recommend

Usefulness

Secondary outcome measures

Cumulative Symptom Burden

POSTHOC Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: POSTHOC appExperimental Treatment1 Intervention

Group II: ControlActive Control1 Intervention

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,672 Previous Clinical Trials

40,926,387 Total Patients Enrolled

Charles River AnalyticsIndustry Sponsor

2 Previous Clinical Trials

89 Total Patients Enrolled

University of Maryland, BaltimoreLead Sponsor

688 Previous Clinical Trials

374,602 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals currently able to participate in this ongoing medical study?

"As indicated on clinicaltrials.gov, this trial is actively pursuing eligible participants. The study was first listed on March 5th, 2024, and the latest update was made on March 12th, 2024."

Answered by AI

What is the cap on participant enrollment for this research investigation?

"Affirmative. Information from clinicaltrials.gov indicates that this trial is presently enrolling participants. The trial was initially listed on March 5th, 2024, and last revised on March 12th, 2024. Enrollment seeks to include a total of 54 patients at a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Title: Leveraging Technology to Address Health Outcomes of Cancer Survivors

Amber Kleckner 2024. "Title: Leveraging Technology to Address Health Outcomes of Cancer Survivors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05499663.